MELA Electro-Optical Sciences, Inc. featured news, full reports, and detailed charts
Electro-Optical Sciences, Inc. (MELA) Wrap Up:
Electro-Optical Sciences, Inc., a medical device company, engages in the design and development of a non invasive, hand-held imaging, and point-of-care instrument to assist in the early detection of melanoma in the United States and internationally. The company’s principal product, MelaFind, features a hand-held imaging device that emits light of multiple wavelengths to capture images of suspicious pigmented skin lesions and extract data. The data is then analyzed through its proprietary database of melanomas and benign lesions to provide information to the physician and produce a recommendation of whether the lesion should be biopsied. It primarily serves general dermatologists, plastic sur...Electro-Optical Sciences, Inc. (MELA:NASDAQ)
Snapshot of Electro-Optical Sciences, Inc. (MELA)
|
OPEN
$9.27
|
PREVIOUS CLOSE
$9.01
|
|
|
DAY HIGH
$9.80
|
DAY LOW
$9.00
|
|
|
52 WEEK HIGH
10/27/09 - $11.73
|
52 WEEK LOW
11/20/08 - $2.29
|
|
|
MARKET CAP
216.7M
|
AVERAGE VOLUME 3 mo
788.0K
|
|
|
DILUTED EPS TTM
$-0.94
|
SHARES OUTSTANDING
22.2M
|
|
|
MELA Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
MELA Top Compensated Officers
Executives, Board Directors
Key developments for Electro-Optical Sciences, Inc. (MELA)
Electro-Optical Sciences, Inc. expected to Report Q3 2009 Results on November 9, 2009. This event was calculated by Capital IQ (Created on November 5, 2009).
Electro-Optical Sciences, Inc. - Conference Presentation Calls
Electro-Optical Sciences Inc. announced that the U.S. Food and Drug Administration (FDA) formally accepted for filing the company's Pre-Market Approval (PMA) application for MelaFind(R), a non-invasive and objective computer vision system intended to aid in the early detection of melanoma. The FDA's action means that the PMA application was sufficiently complete and ready for substantive review. The filing date for regulatory purposes is June 9, 2009, the date the FDA received EOS' PMA submission. The FDA also confirmed that the PMA application will receive expedited review and processing.
MELA Competitors
| Company | Last | Change | |
| No competitor information is available for MELA. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | MELA | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 8.3x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
MELA |
||
MELA transactions
| Type Date |
Target |
|
Private Placement
July 16, 2009 |
-- |